Opdivo Qvantig™

Understanding Opdivo Qvantig™ 

Opdivo Qvantig™ is a subcutaneous injection formulation of the immunotherapy drug Opdivo® (nivolumab), combined with hyaluronidase-nvhy to facilitate absorption. This formulation offers a more convenient administration method for patients, reducing infusion times from hours to minutes. Opdivo Qvantig™ is approved for most adult solid tumor indications previously treated with intravenous Opdivo®, including use as monotherapy, maintenance therapy post-combination treatment, or in combination with other therapies.

How Opdivo Qvantig™ Works:

• PD-1 Inhibition: Nivolumab blocks the PD-1 pathway, enhancing the body’s immune response against cancer cells.

• Enhanced Absorption: Hyaluronidase-nvhy increases tissue permeability, allowing for efficient subcutaneous delivery of nivolumab.

• Convenient Administration: Provides a subcutaneous injection alternative to intravenous infusions, improving patient comfort and reducing administration time.

FDA Approval:

• Opdivo Qvantig™ was approved by the U.S. Food and Drug Administration (FDA) on December 27, 2024, for subcutaneous use in most previously approved adult solid tumor Opdivo® indications.

For more information, please visit the Opdivo Qvantig™ patient website and speak with your healthcare provider to determine if Opdivo Qvantig™ is the right treatment option for you.